OCULAR Q3 2026 RESULTS - OCULAR THERAPEUTIX INC

Financial Performance:

• Ended Q3 2026 with $530.6 million in cash and cash equivalents.
• Cash runway extends into 2028 based on current burn rates, excluding future commercialization expenses for X-Paxley.
• Maintains disciplined capital allocation while prioritizing regulatory, clinical, and commercial infrastructure investments.
• No specific revenue, earnings, or margin metrics disclosed as the company remains pre-revenue for its investigational product.

Guidance and Future Outlook:

• Targeting NDA submission for X-Paxley (OTX-TKI) in wet AMD during Q4 2026, utilizing the 505(b)(2) pathway to potentially shorten review timelines by ~60 days.
• SOLAR top-line results remain on track for release in Q1 2028; the study remains fully masked through Week 96.
• Anticipates X-Paxley establishing a new standard for maintenance therapy in wet AMD, with potential for a superiority label and premium pricing.
• Expansion into non-proliferative diabetic retinopathy (NPDR) is a long-term growth strategy, with registrational Helios 3 trial progressing and further details expected in 2027.
• Commercial launch preparation is active, with pre-approval payer engagement covering approximately 84% of commercial lives in priority tier accounts.

Business Segments and Product Lines:

• X-Paxley (OTX-TKI): A bioresorbable hydrogel delivering excedinib, a TKI with ~100x greater potency against VEGFR2 than vorolanib; currently the only intravitreal sustained-release agent with positive Phase III data in wet AMD.
• SOL1: Phase 3 superiority trial demonstrated ~75% of patients maintained vision at Week 36 and ~66% at Week 52 following a single injection in a high-risk population.
• SOLAR: Phase 3 non-inferiority trial designed with a 6-month screening/loading period to exclude patients with early persistent fluid; primary endpoint modified from Week 56 to Week 40 to protect statistical integrity against operational bias during interim safety unmasking.
• SOLEX: Long-term open-label extension study modified to test 48-week (annual) dosing intervals, moving from previous 24-week intervals, based on durability data showing >70% of patients remained quantitatively dry at 36 weeks.
• Helios 3: Phase 3 registrational trial in diabetic retinal disease (including NPDR) currently evaluating once-yearly dosing.

Market and Competitive Landscape:

• Positions X-Paxley as a complementary long-term maintenance therapy rather than a direct competitor to bolus anti-VEGF therapies, which are viewed as tools for initial disease control.
• Identifies a significant unmet need: >40% of patients are lost to therapy within the first year due to frequent bolus dosing, while maintenance represents >90% of the wet AMD treatment market.
• Highlights the recent discontinuation of a peer's TKI program as a competitive advantage, leaving X-Paxley as the only late-stage intravitreal sustained-release competitor.
• Emphasizes that rigorous patient selection (excluding those with fluid variability) and TKI potency are critical differentiators that peers failed to replicate in their trials.

Risks and Challenges:

• Regulatory uncertainty remains inherent to the drug approval process, though management expresses high confidence given FDA alignment and the comprehensive safety database (300+ patients with 1-year follow-up).
• Market adoption risks related to payer step-edit requirements are mitigated by the potential for a superiority label and demonstrated durability.
• Clinical trial execution risks are being managed through protocol refinements (e.g., SOLAR endpoint change) to ensure data integrity and statistical power.
• The company faces no approved direct competitors in the late-stage sustained-release maintenance space for wet AMD.

Management Commentary and Tone:

• Tone is highly confident and optimistic, describing 2026 as a "transformational year" and the company as being in its "strongest position in 20-year history."
• Management emphasizes the "fundamental principles" of drug potency, delivery vehicle, and trial design as the drivers of their success compared to competitors.
• CEO Dr. Praveen Dougal and CMO Dr. Nadia Wahid projected strong conviction that X-Paxley will achieve approval based on SOL1 data alone, with SOLAR serving as a secondary commercial/regulatory asset.
• Strategic shift to prioritize commercial expertise highlighted by the appointment of Dr. Riyadh Sharif (ex-Alcon, Novartis, Sanofi) to the Board of Directors.

Analyst Questions and Answers:

• SOLAX Dosing Interval: Management confirmed the shift to 48-week dosing in SOLEX is driven by high confidence in durability and FDA alignment, aiming to provide evidence for annual maintenance in stable patients.
• SOLAR Endpoint Change: The move from Week 56 to Week 40 was a proactive management decision to prevent operational bias during the required interim safety unmasking for the NDA; it incurs a negligible alpha penalty (0.0001) and is fully aligned with FDA guidance.
• NDA Requirements: The NDA submission will include only safety data from SOLAR at Week 52 to meet the 300-patient exposure requirement, without unmasking efficacy data. The study will remain masked until Week 96.
• Label Expectations: Management expects a label highlighting superiority and flexible dosing (every 6 to 12 months), potentially avoiding traditional step edits.
• Repeat Dosing Safety: The regulatory package will include repeat dosing data from both SOL1 and SOLAR patients, totaling over 300 subjects with at least one year of follow-up on multiple injections.

Other Key Points:

• X-Paxley demonstrated "quantitatively dry" status (<10 nanoliters of fluid) in ~70% of subjects at 36 weeks using AI-based assessment.
• Post-hoc analysis of SOL1 identified that early persistent fluid is a predictor of treatment failure, reinforcing the value of SOLAR's 6-month screening period.
• The 505(b)(2) regulatory pathway is expected to reduce review time by up to 60 days compared to a traditional 505(b)(1) New Molecular Entity application.
• The company maintains a comprehensive roadmap for clinicians involving bolus initiation followed by X-Paxley maintenance.